Last reviewed · How we verify
Perlane
At a glance
| Generic name | Perlane |
|---|---|
| Also known as | Hyaluronan; Hyaluronate Sodium; Hyaluronic Acid |
| Sponsor | The Cleveland Clinic |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants (PHASE3)
- Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency (NA)
- Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root (NA)
- Pain and Safety of Restylane Perlane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds (NA)
- Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population (NA)
- Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial Folds (NA)
- Clinical Trial of YYD701-2 for Treatment of Nasolabial Folds (PHASE3)
- Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perlane CI brief — competitive landscape report
- Perlane updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI